A Randomized, Double-blind, Vehicle-Controlled, Phase II/Ⅲ Seamless Adaptive Clinical Trail to Evaluate the Efficacy and Safety of SHR0302 Ointment in Adult Patients With Vitiligo
Latest Information Update: 14 Jul 2022
At a glance
- Drugs Ivarmacitinib (Primary)
- Indications Vitiligo
- Focus Registrational; Therapeutic Use
- Sponsors Reistone Biopharma
- 11 Jul 2022 Status changed from recruiting to discontinued.
- 04 Mar 2021 New trial record